How We’ve Been Cashing In On The GLP-1 Craze

How We’ve Been Cashing In On the GLP-1 Craze

The booming market for weight-loss drugs, particularly GLP-1 agonists, have led to substantial gains in drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY). The latter is seeing its share price approach the $1,000 level, putting it out of reach for most investors.

But we’ve been able to generate thousands of dollars from LLY over the past year and boost our rates of return using a simple options-selling strategy.

Mission, Vision & Values

Meet the Team

Traders Reserve Community Hub

Each day, you’ll discover trends and stocks to help you be a smarter investor delivered to your inbox or mobile phone.





Weekly Income Plan

Perpetual Income

Weekend Cash

Options Income Weekly

Perpetual Income

Income Masters

Options Trader Pro

Weekly Income Plan

Income Madness

Weekend Cash

Investor’s Blueprint Live

Millionaire’s Trading Club

Live Options Trading